Loading...
•
Jun 30
Zoetis Q2 2025 Earnings Report
Zoetis reported solid Q2 results with strong growth in companion animal products and raised full-year guidance.
Key Takeaways
Zoetis delivered strong Q2 2025 results with $2.5B in revenue and $718M in net income, driven by an 8% increase in companion animal sales. The company raised its full-year 2025 outlook based on continued disciplined execution and robust performance in the first half.
Revenue grew to $2.5B with 8% organic growth
Net income increased to $718M, up 15% YoY
Adjusted EPS reached $1.76
Full-year 2025 revenue and EPS guidance raised
Zoetis
Zoetis
Zoetis Revenue by Segment
Zoetis Revenue by Geographic Location
Revenue by Segment
Companion Animal Revenue
CapyFin.comLivestock Revenue
CapyFin.comContract Mfg. & Human Health Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Zoetis raised its full-year 2025 guidance for revenue, net income, and adjusted EPS, reflecting strong first-half execution.
Positive Outlook
- Revenue guidance raised to $9.45B–$9.6B
- Adjusted EPS guidance raised to $6.30–$6.40
- Net income guidance increased to $2.65B–$2.7B
- Adjusted net income guidance increased to $2.825B–$2.875B
- Organic revenue growth outlook raised to 6.5%–8%
Challenges Ahead
- Livestock segment continues to face headwinds
- Divestiture of medicated feed additive portfolio impacts growth
- Ongoing foreign exchange pressure on international revenue
- Flat growth in some developed international markets
- Competitive pressure on certain livestock products like Draxxin
Revenue & Expenses
Visualization of income flow from segment revenue to net income